Medical Condition News

RSS

New journal on cancer biology and genetics

SAGE announces Genes & Cancer, a monthly journal edited by Dr. Prem Reddy, founder and previous Editor-in-Chief of the prestigious and highly-ranked Oncogene.

6 Oct 2009

Butler Hospital leads clinical study for effectiveness and safety of DBS for OCD

Butler Hospital in Providence, R.I., is leading a clinical study evaluating the effectiveness and safety of deep brain stimulation (DBS) for severe obsessive-compulsive disorder (OCD).

6 Oct 2009

ResMed announces acquisition of Laboratoires Narval

ResMed Inc. (NYSE: RMD), a leading developer, manufacturer and distributor of sleep and respiratory medical equipment, announced today that it has acquired Laboratoires Narval. Based in France, Laboratoires Narval manufactures and distributes the Narval O.R.M.(TM), an innovative mandibular repositioning device (MRD) that offers a solution to patients for snoring and obstructive sleep apnea (OSA), especially for those with mild OSA.

From ResMed Corp 6 Oct 2009

Campbell Soup's initiative to help reduce obesity

Campbell Soup Company is proud to team up with fellow members of the food and beverage industry, its retail customers and non-governmental organizations as part of the Healthy Weight Commitment Foundation to help reduce obesity by 2015.

6 Oct 2009

Eat strawberries to improve cholesterol levels

According to a new study published in the October 2009 issue of Nutrition Journal, women with metabolic syndrome had reduced total cholesterol levels - including LDL - after a brief period of daily consumption of a strawberry-based beverage.

6 Oct 2009

$16 million federal stimulus funds for cancer research projects

Researchers at Fred Hutchinson Cancer Research Center, Group Health Research Institute and the University of Washington schools of Public Health and Pharmacy have been selected to lead four projects backed by approximately $16 million in federal stimulus funding for comparative-effectiveness research in cancer.

6 Oct 2009

Pomegranate juice beneficial for patients with elevated cardiovascular disease risk factors: Study

According to a clinical study released in The American Journal of Cardiology, a daily serving of POM Wonderful 100% Pomegranate Juice may decrease the progression of arterial plaque in patients with elevated cardiovascular disease risk factors. The study was intended to see if POM Wonderful 100% Pomegranate Juice may slow the progression of intima-media thickness of the carotid artery (CIMT) in patients with moderate coronary heart disease risk.

6 Oct 2009

Guided Therapeutics awarded $2.5M NCI grant for marketing LightTouch technology

Guided Therapeutics, Inc. today announced that it was awarded a $2.5 million matching grant by the National Cancer Institute (NCI) to bring to market and expand the array features for its LightTouch™ non-invasive cervical cancer detection technology. The award provides resources to complete the regulatory process and begin manufacturing ramp up for the device and single-patient-use disposable.

6 Oct 2009

Antibiotic minocycline may be used for treatment of strokes: Study

The antibiotic minocycline may revolutionize the treatment of strokes. A new study, published in the open access journal BMC Neuroscience, describes the safety and therapeutic efficacy of the drug in animal models.

6 Oct 2009

Uncontrolled maternal asthma during pregnancy increases the likelihood of the child developing asthma

Expectant mothers who eschew asthma treatment during pregnancy heighten the risk transmitting the condition to their offspring, according to one of the largest studies of its kind published in the European Respiratory Journal.

5 Oct 2009

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

Bristol-Myers Squibb Company and AstraZeneca announced today that the European Commission has granted marketing authorisation for ONGLYZATM in the 27 countries of the European Union.

5 Oct 2009

CSL Behring - Canada Research Chair to develop therapies for treating bleeding and immune system disorders

The Centre for Blood Research (CBR) and the Faculty of Medicine at the University of British Columbia have announced the establishment of the CSL Behring - Canada Research Chair in Endothelial Cell Biology. Over the next five years, the CBR and CSL Behring Canada, the biopharmaceutical company co-funding the chair program, will collaborate on the research and development of new therapies for patients with bleeding and immune system disorders.

5 Oct 2009

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

ArQule, Inc. (Nasdaq: ARQL) today announced that patient enrollment in a Phase 2 trial with ARQ 197 in non-small cell lung cancer (NSCLC) has been completed.

5 Oct 2009

Alnara to announce Phase 3 study results of liprotamase for treating cystic fibrosis at the 23rd NACFC

Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota.

5 Oct 2009

Supportive housing program is cost-effective option for people with mental illness

In the wake of a landmark decision by Federal District Judge Nicholas Garaufis, who in early September ruled that New York State is violating the Americans with Disabilities Act by segregating individuals with mental illness from the general population and fostering "learned helplessness," detrimental to rehabilitation and recovery, Community Access is inviting neighbors, local businesses and friends to tour its supportive housing sites in New York City this October

5 Oct 2009

VIVUS to present data on Qnexa at The Obesity Society meeting

VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.

5 Oct 2009

FDA grants Impax tentative approval of ANDA for FLOMAX generic version

Impax Laboratories, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company’s Abbreviated New Drug Application (ANDA) for generic version of FLOMAX® (tamsulosin hydrochloride) 0.4mg capsules. Boehringer Ingelheim Pharmaceuticals, Inc. markets FLOMAX® for the functional symptoms of benign prostatic hyperplasia.

5 Oct 2009

Positive results from Peregrine's Phase II bavituximab trial for non-small cell lung cancer

Peregrine Pharmaceuticals, Inc. today reported additional positive results in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Data previously reported from the initial cohort of 21 patients in the study had indicated that 11 of 17 evaluable patients with locally advanced or metastatic NSCLC achieved an objective tumor response according to RECIST criteria.

5 Oct 2009

avVaa World Health Care Products launches Neuroskin Psoriasis Relief DRTV media test campaign

avVaa World Health Care Products Inc. a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced the launch of its two week Neuroskin(R) Psoriasis Relief DRTV media test campaign.

5 Oct 2009

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Seattle Genetics, Inc. announced today that it has discontinued the SeaGen MARINER clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of superior complete response rate in the dacetuzumab combination arm as compared to the placebo combination arm.

5 Oct 2009

Medical Condition News

New journal on cancer biology and genetics

Butler Hospital leads clinical study for effectiveness and safety of DBS for OCD

ResMed announces acquisition of Laboratoires Narval

Campbell Soup's initiative to help reduce obesity

Eat strawberries to improve cholesterol levels

$16 million federal stimulus funds for cancer research projects

Pomegranate juice beneficial for patients with elevated cardiovascular disease risk factors: Study

Guided Therapeutics awarded $2.5M NCI grant for marketing LightTouch technology

Antibiotic minocycline may be used for treatment of strokes: Study

Uncontrolled maternal asthma during pregnancy increases the likelihood of the child developing asthma

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

CSL Behring - Canada Research Chair to develop therapies for treating bleeding and immune system disorders

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

Alnara to announce Phase 3 study results of liprotamase for treating cystic fibrosis at the 23rd NACFC

Supportive housing program is cost-effective option for people with mental illness

VIVUS to present data on Qnexa at The Obesity Society meeting

FDA grants Impax tentative approval of ANDA for FLOMAX generic version

Positive results from Peregrine's Phase II bavituximab trial for non-small cell lung cancer

avVaa World Health Care Products launches Neuroskin Psoriasis Relief DRTV media test campaign

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News